Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
Open Access
- 1 May 2009
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 373 (9676) , 1681-1692
- https://doi.org/10.1016/s0140-6736(09)60740-6
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK (CRUK 01/001)
- Roche
This publication has 41 references indexed in Scilit:
- Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapyAdvances in Enzyme Regulation, 2008
- Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197Journal of Clinical Oncology, 2008
- Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Triple negative tumours: a critical reviewHistopathology, 2007
- Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast CancerClinical Cancer Research, 2007
- Adjuvant Docetaxel for Node-Positive Breast CancerNew England Journal of Medicine, 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983